Literature DB >> 12923384

New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension.

Peter Sleight1, Salim Yusuf.   

Abstract

We reviewed the drug treatment of hypertension in the light of recent trials. beta-Blockers and diuretics clearly reduce mortality, strokes, and coronary heart disease (CHD) in hypertension. Recent trials assessed whether newer agents that block the renin-angiotensin-aldosterone system, or calcium blockers, offer any additional advantage, or have benefits in high-risk individuals with conventionally 'normal' blood pressure. The recent ALLHAT study claimed no differences in CHD or mortality when chlorthalidone, amlodipine, and lisinopril were compared. However, the decrease in blood pressure was not the same with the three agents, and a substantial proportion of patients enrolled did not have clinical disease. In contrast, the LIFE study (comparing losartan and a beta-blocker) and the ANBP-2 study [comparing angiotensin-converting enzyme (ACE) inhibition and a diuretic] reduced blood pressure similarly, yet demonstrated benefits in favour of angiotensin II type 1 receptor blockers (ARBs) and ACE inhibitors. Other trials indicated similar advantages of ACE inhibitors or ARBs in patients with diabetic nephropathy. Among high-risk patients with initial blood pressure in the 'normal' range, ACE inhibitors significantly reduce clinical events (mortality, strokes, and myocardial infarction), despite modest decreases in blood pressure, suggesting that additional mechanisms are responsible. Recent results of the Prospective Studies Collaboration show lower risk, even in the normal blood pressure range; high-risk patients will benefit further from ACE inhibitors and ARBs (and beta-blockers after myocardial infarction). Data for other blood pressure decreasing agents are unavailable in such populations. We conclude that blood pressure decreasing per se is of clinical benefit, but drugs that block the renin-angiotensin system offer additional advantages. Drug choice is best determined by the patient's clinical condition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12923384     DOI: 10.1097/00004872-200309000-00001

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  5 in total

1.  Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects.

Authors:  Sujata Vaidyanathan; Joanne Jermany; Chingming Yeh; Marie-Noelle Bizot; Riccardo Camisasca
Journal:  Br J Clin Pharmacol       Date:  2006-12       Impact factor: 4.335

2.  Effects of job strain on blood pressure: a prospective study of male and female white-collar workers.

Authors:  Chantal Guimont; Chantal Brisson; Gilles R Dagenais; Alain Milot; Michel Vézina; Benoît Mâsse; Jocelyne Moisan; Nathalie Laflamme; Caty Blanchette
Journal:  Am J Public Health       Date:  2006-06-29       Impact factor: 9.308

Review 3.  Hypertension and the metabolic syndrome.

Authors:  John A Farmer
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

Review 4.  Clinical pharmacokinetics and pharmacodynamics of aliskiren.

Authors:  Sujata Vaidyanathan; Venkateswar Jarugula; Hans Armin Dieterich; Dan Howard; William P Dole
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 5.  Thiopeptide antibiotics: retrospective and recent advances.

Authors:  Xavier Just-Baringo; Fernando Albericio; Mercedes Álvarez
Journal:  Mar Drugs       Date:  2014-01-17       Impact factor: 5.118

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.